Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB074 in participants with neuropathic Pain From Lumbosacral Radiculopathy (PLSR). A secondary objective is to investigate the maintenance of effect during long-term treatment with BIIB074 in participants with neuropathic PLSR. For all efficacy assessments, baseline will be prior to randomization into Study 1014802-203. Another secondary objective is to evaluate the impact of treatment with BIIB074 on quality of life (QoL).


Clinical Trial Description

This study was previously posted by Convergence Pharmaceuticals, Ltd., which has been acquired by Biogen. This is an extension study to 1014802-203. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02957617
Study type Interventional
Source Biogen
Contact
Status Terminated
Phase Phase 2
Start date February 10, 2017
Completion date February 7, 2019